Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:50:10 EDT Sun 24 May 2026
Enter Symbol
or Name
USA
CA



Q:DYN - DYNE THERAPEUTICS INC - https://www.Dynegy.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
DYN - Q6.317.39·19.530.117.371,448.124,58913,16717.21  17.965  17.1525.00  8.0616:54:50May 2015 min RT 2¢

Recent Trades - Last 10 of 13167
Time ETExPriceChangeVolume
16:54:50Q17.520.1540
16:54:50Q17.390.0260
16:15:33Q17.520.1560
16:10:04Q17.37 1
16:10:04Q17.37 1
16:10:04Q17.37 1
16:10:04Q17.37 1
16:04:52Q17.37 1
16:04:46Q17.37 1
16:04:26Q17.37 1

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-20 17:30U:DYNNews ReleaseDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-20 07:46U:DYNNews ReleaseDyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
2026-05-13 07:30U:DYNNews ReleaseDyne Therapeutics to Participate in Upcoming Investor Conferences
2026-05-11 07:30U:DYNNews ReleaseDyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-04-27 16:34U:DYNNews ReleaseDyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE(TM) Platform at 2026 ASGCT Annual Meeting
2026-04-23 16:05U:DYNNews ReleaseDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-01 07:30U:DYNNews ReleaseDyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
2026-03-08 18:01U:DYNNews ReleaseDyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
2026-03-08 18:00U:DYNNews ReleaseDyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
2026-03-02 07:30U:DYNNews ReleaseDyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
2026-02-25 07:30U:DYNNews ReleaseDyne Therapeutics to Participate in Upcoming Investor Conferences
2026-02-22 16:00U:DYNNews ReleaseDyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
2026-01-20 07:30U:DYNNews ReleaseDyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
2026-01-07 07:30U:DYNNews ReleaseDyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
2025-12-23 07:30U:DYNNews ReleaseDyne Therapeutics Appoints Vikram Karnani to Board of Directors
2025-12-11 16:05U:DYNNews ReleaseDyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
2025-12-09 21:43U:DYNNews ReleaseDyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
2025-12-08 16:02U:DYNNews ReleaseDyne Therapeutics Announces Proposed Public Offering of Common Stock
2025-12-08 06:30U:DYNNews ReleaseDyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
2025-12-07 11:00U:DYNNews ReleaseDyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET